In conclusion, our preclinical finding strongly demonstrated that a multiple inhibition of Akt could represent a new promising therapeutic strategy to overcome relapse or resistance in the treatment of T- ALL patients with hyperactivated PI3K/Akt/mTOR signaling pathway. Here, AKT1 is linked to acute lymphoblastic leukemia.